| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.32 | 8e-08 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.3 | 1e-07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.22 | 5e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.21 | 1e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.21 | 7e-05 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.2 | 0.0005 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.005 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.14 | 0.005 |